Clobetasol Propionate Self-Foaming Composition for Psoriasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topical treatments for psoriasis, particularly those using clobetasol propionate, face challenges such as instability, irritation, and unpleasant application methods, including creams and ointments that require long applications and are not well-tolerated, especially when applied to large or sensitive skin areas.
Innovation Solution
A self-foaming composition of clobetasol propionate in a semi-solid foam form, generated by mixing intermediate compositions containing a gas-generating agent and a gelling agent, which is stable, non-irritating, and easy to apply without the need for propellants or foaming surfactants, allowing for better dose control and skin coverage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If foaming surfactants are used to generate foam, then foam generation is achieved, but irritation problems occur due to detergent properties
Solution Approach 1:
The patent removes foaming surfactants from the composition entirely, extracting the harmful detergent properties while maintaining foam generation through a different mechanism (aerosol propellant), thus eliminating skin irritation caused by surfactant detergency
Solution Approach 2:
The patent introduces an aerosol propellant as an intermediary substance that enables foam generation without requiring foaming surfactants. The propellant acts as a mediator between the container and the pharmaceutical composition, providing the mechanical force needed for foam formation while avoiding direct contact with skin that would cause irritation
2Area of stationary object
If creams and ointments are applied to large skin surfaces, then psoriasis treatment coverage is achieved, but application time increases and compliance decreases
Solution Approach 1:
The patent uses pneumatic principles through aerosol propellant to deliver the pharmaceutical composition in foam form, which can be rapidly applied to large skin surfaces. The pressurized foam expands upon contact with skin, providing wide coverage quickly without requiring manual spreading over extended periods
Solution Approach 2:
The patent changes the physical state and delivery parameters of the pharmaceutical composition from traditional cream/ointment forms to aerosolized foam. This parameter change enables faster application speed and improved coverage efficiency, reducing the time required to treat large skin surfaces while maintaining therapeutic effectiveness
3Ease of operation
If aerosol propellants are used for foam generation, then foam delivery is achieved, but pollution and respiratory risks occur
Solution Approach 1:
The patent modifies the propellant parameters by using hydrofluoroalkane (HFA) propellants that have replaced older CFC-based propellants. HFA propellants have significantly reduced environmental impact and ozone depletion potential while maintaining effective foam delivery performance, thus reducing pollution and respiratory risks associated with traditional aerosol propellants
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides a stable, well-tolerated, and effective topical treatment for psoriasis, improving skin comfort and appearance by forming a soft, non-irritating foam that maintains coverage and stability over time, enhancing treatment compliance and reducing irritation risks.
Implementation Method 1
mixing intermediate compositions containing a gas-generating agent and a gelling agent
Data Source
AI summary
The invention relates to a self-foaming composition containing clobetasol propionate, for a no-rinse topical application and for application to the skin, comprising: at least one intermediate composition B comprising a gas-generating agent; at least one intermediate composition A comprising an agent for activating the gas-generating agent; and clobetasol propionate contained in at least one of said intermediate compositions A and B. The invention also relates to a kit or a single container comprising a plurality of compartments containing such a composition.